Administration of CAR T-cells at 3 different not checked

Kure Cells, INC

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
1 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“The patients will receive one of 3 dose levels as outlined above.”In the company’s words, NCT07611149 on ClinicalTrials.gov
Tested for
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Main trialPhase 1
“The goal of this study is to evaluate the safety of a new type of CAR T-cell, UF-KURE-BCMA, for the treatment of patients with advanced multiple myeloma that has not responded to other therapies. The main question is whether the use of these new CAR T-cells is safe for patients with this condition. Secondarily, the study will also look at the response of myeloma to this therapy.”In the company’s words, NCT07611149 on ClinicalTrials.gov

Other drugs for Multiple Myeloma in Relapse

All 133 drugs for Multiple Myeloma in Relapse

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Not yet recruiting 30 Sep 2028 Study to Evaluate the Safety of UF-KURE-BCMA CAR T-Cells in Advanced Myeloma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Administration of CAR T-cells at 3 different

Following is part of Solo: you see every change to Administration of CAR T-cells at 3 different the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in